Practical Cure Portfolio Update: Q3 2026

JDCA is excited to announce the second publication of our Practical Cure Portfolio! The portfolio provides an update on 44 companies working toward one or more components of a Practical Cure for T1D. Tracked companies range from fledgling startups to well-established leaders in the pharmaceutical arena, testing across animal models and human clinical trials. 

All have real cure potential. 

Today, it remains the only publication assessing companies' financial strength and potential T1D impact.

In recent years, T1D research has advanced meaningfully. Methods to restore lost insulin-producing cells and novel ways to protect them are returning results in clinical trials. This progress has drawn increasing attention from for-profits, investing more resources, attention, and capital from entities both large and small.

It is important to track these companies because any Practical Cure solution will need to move through for-profit hands to reach patients living with the disease today. For-profits are uniquely motivated to get a product to market with urgency. 
 

Highlights

• Practical Cure Pathways: At-a-glance insight into which companies are working on cell supply, protection, or complete Practical Cure solutions.
• Research Progress: Three companies advanced their T1D program across the development pipeline, while a fourth receded.
• Milestones: Overview of T1D research milestones met in Q3 and those anticipated by year-end.
• Performance Highlights: Key financial and T1D research news announced in Q3. 
• Ranked Performance: Q3 and YTD analysis of company performance.